Azithromycin

Generic Name: Azithromycin

Brand Names: Azasite, Zithromax, Zmax

Drug Type: Small Molecule

Chemical Formula: C_₃₈H_₇₂N_₂O_₁₂

CAS Number: 83905-01-5

Unique Ingredient Identifier: J2KLZ20U1M

Background: Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration . It was initially approved by the FDA in 1991 .
...

Indication: Azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin .
...

Associated Conditions: Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Acute bacterial exacerbation of COPD caused by Haemophilus Influenza Infections, Moraxella Catarrhalis Infection, Streptococcus Pneumoniae Infections, Bacterial Conjunctivitis, Bacterial Sinusitis, Cervicitis, Chancroid, Community Acquired Pneumonia (CAP), Genital Ulcer Disease (GUD), Pelvic Inflammatory Disease (PID), Pharyngitis, Streptococcal Pharyngitis, Tonsillitis bacterial, Tonsillitis streptococcal, Traveler's Diarrhea, Uncomplicated Skin and Skin Structure Infections, Urethritis

Associated Therapies: -

Clinical Trials

Study to Measure the Impact of Antibiotics on Bacterial Flora in Adults With Acute Sinusitis

Phase 4

Terminated

Conditions: Maxillary Sinusitis

Interventions: Drug: Telithromycin
Drug: Azithromycin

First Posted Date: 2005-10-28

Last Posted Date: 2007-10-31

Lead Sponsor: CPL Associates

Target Recruit Count: 192

Registration Number: NCT00245440

Locations: 🇺🇸
Southeastern Researchs Associates,Inc., Taylors, South Carolina, United States

Study Comparing the Clinical Efficacy and Health Outcomes of Outpatients With Mild to Moderate Community-Acquired Pneumonia (CAP) Treated With Either Telithromycin Once Daily for 7 Days, or Azithromycin Once Daily for 5 Days

Phase 4

Terminated

Conditions: Pneumonia

First Posted Date: 2005-10-12

Last Posted Date: 2011-01-11

Lead Sponsor: Sanofi

Target Recruit Count: 110

Registration Number: NCT00237445

Locations: 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States

Single Dose Azithromycin in the Treatment of Adult Cholera

Phase 3

Completed

Conditions: Cholera

First Posted Date: 2005-09-30

Last Posted Date: 2006-07-21

Lead Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh

Target Recruit Count: 220

Registration Number: NCT00229944

Locations: 🇧🇩
Dhaka Hospital, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh

Pharmacokinetics and Pharmacodynamics and Selected Antibiotics During Pregnancy

Completed

Conditions: Pregnancy

Interventions: Drug: azithromycin
Drug: gentamicin
Drug: ciprofloxacin

First Posted Date: 2005-09-21

Last Posted Date: 2016-10-27

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 150

Registration Number: NCT00214331

Locations: 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States

Macrolides to Prevent Exacerbations of Asthma and Chronic Obstructive Pulmonary Disease

Phase 2

Terminated

Conditions: Asthma
Chronic Obstructive Pulmonary Disease

First Posted Date: 2005-09-16

Last Posted Date: 2013-05-13

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 18

Registration Number: NCT00181272

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

Zithromax EV in Community-Acquired Pneumonia (CAP)

Phase 4

Completed

Conditions: Pneumonia

First Posted Date: 2005-08-29

Last Posted Date: 2011-04-22

Lead Sponsor: Pfizer

Target Recruit Count: 151

Registration Number: NCT00137007

Prophylactic Antibiotic Treatment of Patients With Chronic Obstructive Lung Disease (COLD)

Phase 4

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2005-08-22

Last Posted Date: 2005-10-19

Lead Sponsor: Odense University Hospital

Target Recruit Count: 800

Registration Number: NCT00132860

Locations: 🇩🇰
Odense University Hospital, Odense, Denmark

KEYS: Study Comparing Clinical Health Outcomes of Telithromycin Versus Azithromycin in Outpatients With Community-acquired Lower Respiratory Tract Infections

Phase 4

Terminated

Conditions: Respiratory Tract Infections
Chronic Bronchitis
Pneumonia

First Posted Date: 2005-08-22

Last Posted Date: 2009-08-27

Lead Sponsor: Sanofi

Target Recruit Count: 2051

Registration Number: NCT00132951

Locations: 🇨🇦
Sanofi-Aventis Administrative Office, Québec, Canada

Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness

Phase 2

Completed

Conditions: Onchocerciasis

First Posted Date: 2005-08-08

Last Posted Date: 2024-08-15

Lead Sponsor: Centers for Disease Control and Prevention

Target Recruit Count: 80

Registration Number: NCT00127504

Locations: 🇬🇹
Universidad del Valle/MERTU, Guatemala City, Guatemala

Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)

Phase 3

Completed

Conditions: Bacterial Conjunctivitis

Interventions: Drug: AzaSite
Other: Vehicle

First Posted Date: 2005-03-16

Last Posted Date: 2013-11-21

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 685

Registration Number: NCT00105534

Locations: 🇺🇸
Taustine Eye Center, Louisville, Kentucky, United States
🇺🇸
Charlotte Eye, Ear, Nose, and Throat, Charlotte, North Carolina, United States
🇺🇸
Precision Eye Care, Huntington, New York, United States

and more 29 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy